Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Update

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 10,800 shares, an increase of 18.7% from the November 30th total of 9,100 shares. Based on an average daily volume of 18,700 shares, the days-to-cover ratio is presently 0.6 days. Approximately 1.7% of the company’s shares are short sold.

Titan Pharmaceuticals Stock Down 2.5 %

Shares of NASDAQ:TTNP traded down $0.09 during trading on Friday, hitting $3.52. The stock had a trading volume of 42,362 shares, compared to its average volume of 131,236. The firm’s fifty day moving average is $3.82 and its 200 day moving average is $5.08. Titan Pharmaceuticals has a 12 month low of $3.12 and a 12 month high of $14.80.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Titan Pharmaceuticals in a research note on Friday. They issued a “sell” rating for the company.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.